(주)헬릭스미스기업정보

About Helixmith
On the edge of a major breakthrough in plasmid DNA-based gene therapy
Founded in 1996, Helixmith has been dedicated to research in gene therapy for over 20 years. Led by Sunyoung Kim and his lab in Seoul National University, the Helixmith team has developed an extremely powerful gene expression system and has tested it in various therapeutic areas.
So far, more than 700 patients have gone through clinical studies using the product, which appears to have an excellent safety profile and promising therapeutic outcomes.
Based on our proprietary technology and know-how gained from 20 years of gene therapy experience, we are researching new approaches to tackle previously untreated diseases. For example, cell-mediated gene therapy is one of the areas in which our efforts are focused on ways that could expand CAR-T programs to treat solid tumors. We also drive innovation through early stage pipeline products that target various neuromuscular diseases.
The company is currently headquartered in Seoul, Korea; our clinical development and manufacturing activities are based in San Diego, California in the US. In particular, we co-own a cGMP-ready DNA production facility, Genopis, Inc., an affiliated CDMO in San Diego. Genopis serves both Helixmith and external customers in need of DNA.

주요 사업내용 : 유전공학적기법을 이용한 연구용 시약 및 바이오의약품 연구개발주요 취급품목 : 연구용시약, 심장질환제, 혈소판감소증치료제, 레트로바이러스, 재조합아데노바이러스